Preliminary results of models to predict areas in the Americas with increased likelihood of Zika virus transmission in 2017

The ZIKAVAT Collaboration*

*Zika Modeling and Projections for Vaccination Trials Collaboration (in alphabetical order): Jason Asher¹, Christopher Barker², Grace Chen³, Derek Cummings^{4,5}, Matteo Chinazzi⁶, Shelby Daniel-Wayman³, Marc Fischer⁷, Neil Ferguson⁸, Dean Follman³, M. Elizabeth Halloran^{9,10}, Michael Johansson⁷, Kiersten Kugeler⁷, Jennifer Kwan³, Justin Lessler⁴, Ira M. Longini⁵, Stefano Merler¹¹, Andrew Monaghan¹², Ana Pastore y Piontti⁶, Alex Perkins¹³, D. Rebecca Prevots³, Robert Reiner¹⁰, Luca Rossi¹⁴, Isabel Rodriguez-Barraquer^{4,15}, Amir S. Siraj¹³, Kaiyuan Sun⁶, Alessandro Vespignani⁶, Qian Zhang⁶.

¹Biomedical Advanced Research and Development Authority, Washington, DC, USA;

²University of California, Davis, California, USA; ³National Institutes of Health, Bethesda, MD, USA; ⁴Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland, USA;

⁵University of Florida, Gainesville, Florida, USA; ⁶Northeastern University, Boston, Massachusetts, USA; ⁷Centers for Disease Control and Prevention, Fort Collins, Colorado and San Juan, Puerto Rico, USA; ⁸Imperial College, London, UK; ⁹Fred Hutchinson Center, Seattle, WA, USA; ¹⁰University of Washington, Seattle, Washington, USA; ¹¹Bruno Kessler Foundation, Trento, Italy; ¹²National Center for Atmospheric Research, Boulder, Colorado, USA; ¹³University of Notre Dame, Notre Dame, Indiana, USA; ¹⁴Institute for Scientific Interchange Foundation, Turin, Italy; ¹⁵University of California, San Francisco, California, USA.

Corresponding author: Marc Fischer, Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado, mfischer@cdc.gov.

Abstract

Numerous Zika virus vaccines are being developed. However, identifying sites to evaluate the efficacy of a Zika virus vaccine is challenging due to the general decrease in Zika virus activity. We compare results from three different modeling approaches to estimate areas that may have increased relative risk of Zika virus transmission during 2017. The analysis focused on eight priority countries (i.e., Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama, and Peru). The models projected low incidence rates during 2017 for all locations in the priority countries but identified several subnational areas that may have increased relative risk of Zika virus transmission in 2017. Given the projected low incidence of disease, the total number of participants, number of study sites, or duration of study follow-up may need to be increased to meet the efficacy study endpoints.

Introduction

Zika virus is a mosquito-borne flavivirus primarily transmitted to humans by *Aedes (Stegomyia)* species mosquitoes [Petersen 2016]. The virus was first identified in Uganda in 1947 [Dick 1952]. Prior to 2007, only sporadic human disease cases were reported from countries in Africa and Asia. From 2007–2014, outbreaks were identified in Southeast Asia and the Western Pacific [Duffy 2009; Heang 2012; Cao-Lormeau 2013; Roth 2014]. In 2015, Zika virus was identified for the first time in the Americas with large outbreaks reported in Brazil and subsequent spread throughout the region [Zanluca 2015; Ikejezie 2017].

Most Zika virus infections are asymptomatic [Duffy 2009]. For patients with symptomatic illness, disease is generally mild and characterized by acute onset of fever or rash. However, Zika virus infection during pregnancy can cause adverse outcomes such as fetal loss, congenital microcephaly, and other serious birth defects [Moore 2017; Rasmussen 2016]. There are no vaccines to prevent Zika virus infection. However, numerous candidate vaccines are being developed and several have entered clinical trials [Thomas 2017].

The National Institutes of Health (NIH) Vaccine Research Center is conducting a Phase 2B clinical trial to evaluate the safety, immunogenicity, and efficacy of a Zika virus DNA vaccine in healthy adolescents and adults. The study will begin in July 2017 and will be performed at multiple sites in the Americas. The current protocol proposes to enroll 2,400 subjects randomized on a 1:1 basis to receive the study vaccine or placebo. Assuming a 50% vaccine efficacy, the study could be completed in approximately 2 years if the average annual incidence of symptomatic Zika virus disease among participants receiving placebo is $\geq 2\%$. The sample size or study duration will need to be increased if the symptomatic disease rate among participants is $< 2\%$ or if $> 10\%$ of the participants are already protected at baseline.

Many factors impact the likelihood and rate of ongoing Zika virus infections in a population (e.g., presence and abundance of vector mosquitoes, temperature, precipitation, human mobility, population density, living conditions, and baseline immunity). However, there are limited data and experience for predicting the occurrence and magnitude of future Zika virus disease outbreaks in the Americas. To help with study site selection to meet the efficacy endpoint, NIH and the Centers for Disease Control and Prevention (CDC) requested assistance from three academic groups to adapt and apply existing mathematical models to estimate areas that may have increased likelihood of Zika virus transmission in 2017. Comparing results from three different modeling approaches enables better characterization of the predictive uncertainty due to model and data limitations with higher confidence assigned to predictions for areas where

model agreement is strong. This report synthesizes findings from the three models obtained in early 2017.

Methods

We identified three models that had been developed and used to predict the geographic location or incidence of dengue or Zika virus disease in 2015–2016. Each modeling team was tasked with providing a list of areas in the Americas with the highest probability of Zika virus transmission and estimated infection rates during 2017. Each model used different input variables and output measures, and relied on different units of reporting. Therefore, comparisons were limited to subnational areas within the same countries rather than between countries.

To facilitate comparisons between models, data were aggregated to a state/province level and focused on eight priority countries (i.e., Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama, and Peru). These countries were selected based on their capacity and infrastructure to perform clinical trials, and preliminary assessments of expected Zika virus activity based on surveillance reports and previous experience with dengue and chikungunya viruses.

Modeling Team 1 (MT1)¹

The Global Epidemic and Mobility Model (GLEAM) is a discrete stochastic epidemic computational model based on a meta-population approach in which the world is defined in geographical census areas connected in a network of interactions by human travel fluxes corresponding to transportation infrastructures and mobility patterns [Zhang 2017]. The model includes a multiscale mobility model integrating different layers of transportation networks ranging from long-range airline connections to short-range daily commuting patterns. GLEAM also integrates high-resolution demographic, socioeconomic, temperature, and vector abundance data. The model has been used to analyze the spatiotemporal spread and magnitude of the Zika epidemic in the Americas accounting for seasonal environmental factors and detailed population data. The model is fully stochastic and from any nominally identical initialization (initial conditions and disease model) generates an ensemble of possible epidemic evolutions for epidemic observables, such as newly generated cases, time of arrival of the infection, and number of traveling carriers. The model native grid cell resolution is 25 km x 25 km and cells are aggregated/projected to the desired level of resolution. For the purpose of studying the Zika outbreak, the model outputs include: 1) the median projected infection rate and 95% confidence intervals (95% CI) for each state/province in the eight priority countries (**Tables 1–8**); and 2) the probability that an urban area in any country/territory in the Americas will experience an annual Zika virus infection rate $\geq 10\%$ in 2017 (**Table 9**).

This modeling approach has been used previously to estimate the transmission and spread of pandemic influenza and Ebola [Tizzoni 2012; Gomes 2014; Poletto 2014]. In order to validate the approach for Zika virus, the authors compared model-based projections to independent surveillance reports of numbers of infections in Colombia, microcephaly cases in Brazil, and travel-associated disease cases in the continental United States and Europe [Zhang 2017].

¹MT1 includes Alessandro Vespignani, Ana Pastore y Piontti, Kaiyuan Sun, Matteo Chinazzi, M. Elizabeth Halloran, Ira M. Longini, Stefano Merler, Luca Rossi, and Qian Zhang.

Modeling Team 2 (MT2)²

This approach compares model projections of infection rates with estimates of cumulative infections to date. Locations with a high projected infection rate that have experienced low transmission to date are presumed to be good candidates for vaccine trials because a relatively large portion of the population is still susceptible and likely to become infected before the epidemic subsides. The infection rate projections are informed by spatial layers of variables pertaining to human demography, purchasing power parity, temperature, and vector occurrence probability. Relationships between these variables and infection rates are drawn from the theoretical and empirical literature on other pathogens transmitted by *Aedes aegypti* mosquitoes, and remaining uncertainties in the model's form are calibrated to seroprevalence estimates following introduction of chikungunya or Zika virus in immunologically naïve populations. The result is a spatial layer of location-specific projections of the number of Zika virus infections that are expected to occur in each 5 km by 5 km area across Latin America and the Caribbean [Perkins 2016]. The timeframe for the projected infections is from the beginning of the epidemic until however long it takes for the epidemic to end due to the buildup of sufficient herd immunity. The extent of herd immunity that is sufficient to end the epidemic is positively associated with transmission potential (i.e., a greater proportion of the population must build-up immunity in settings with intense transmission). Although this model does not predict the precise timeframe over which the Zika virus epidemic will run its course, other estimates suggest local epidemics may be extinguished by herd immunity 2–3 years after the initial introduction of Zika virus [Ferguson 2016].

Estimates of cumulative infections to date are based on a combination of cumulative reported cases and assumptions about the proportion of infections that are reported, denoted as p . It is generally accepted that p is extremely variable across settings and difficult to ascertain. Based on discussions among the modeling teams, there is general agreement that p may often be around 1–2%, could sometimes be as high as 5%, and is unlikely to exceed 10% in the settings under consideration. Given this overall uncertainty about p and collective opinion about what values it may likely take, we assumed that $p \sim 0.01 + 0.9\text{Beta}(1.2, 5)$. This implies that the expected value of p is 0.027 and that it does not exceed 0.1 or fall below 0.01. This approach to parameterizing p is similar to formulating a prior probability distribution based on “expert opinion” in a Bayesian analysis. For context, we note a limited number of published estimates of p : 0.015 (95% CI: 0.036–0.022) on Yap Island in 2007 [Duffy 2009]; 0.115 (95% CI: 0.073–0.179) in French Polynesia in 2013–2014 [Kucharski 2016]; 0.021 (95% CI: 0.017–0.025) in Puerto Rico in 2016 [Chevalier 2017]; and 0.010 (standard deviation = 0.0093) across the Americas as a whole in 2013–2016 [Zhang 2017]. Subsequent refinements of this approach will seek to incorporate additional estimates and to more formally characterize uncertainty about p .

The authors then compare the projected number of infections that will occur before the first wave of the epidemic concludes to estimates of the current cumulative incidence of infection to estimate the proportion of the population that remains at risk for infection. Locations with a large discrepancy between numbers of projected total infections and estimated infections to date are interpreted to be good candidates for vaccine trial sites (**Tables 1–8**).

²MT2 includes Alex Perkins, Amir Siraj, Christopher Barker, and Robert Reiner.

Modeling Team 3 (MT3)³

This approach uses the age-specific incidence of dengue to calculate the associated force of infection for dengue per administrative unit [Cummings 2009; Ferguson 2016; Rodriguez-Barraquer 2016]. This hazard of infection previously was shown to correlate with Zika incidence in Colombia and with microcephaly incidence in Brazil. In each country, the relationship between dengue force of infection and reported Zika virus disease incidence (Mexico, Colombia) or microcephaly incidence (Brazil) is calculated based on a presumed linear relationship between the square root of Zika incidence (or a proxy) and the force of infection. A statistical probability score per administrative unit is calculated and is the probability of seeing the number of observed cases or greater for a given force of infection, if the square root of incidence is normally distributed with the predicted mean and observed variance of the residuals. This score is used to rank areas, and can be roughly interpreted as the probability of seeing the observed number of cases or fewer if the Zika epidemic has completed in an area with that force of infection for dengue (**Tables 1–8**).

Integrating the model results

Each province, state, or department in the eight priority countries was ranked according to the primary outcome measure for each of the models that provided data for that country (i.e., all three models for Brazil, Colombia, and Mexico, and models 1 and 2 for Costa Rica, Dominican Republic, Ecuador, Panama, and Peru). The MT3 output was not provided for countries for which age-specific dengue incidence data was unavailable.

The median rank for the available models was calculated and states/provinces were ordered and mapped for each country. The consistency among models was assessed by identifying in each country the states, provinces, or departments ranking within the top quartile by two or more models.

We used data from MT1 to identify states, provinces, or departments with a median projected infection rate $\geq 10\%$ to approximate a symptomatic infection rate $\geq 2\%$ in the eight priority countries, assuming that roughly 20% of cases are symptomatic [Duffy 2009]. We also used Model 1 data to identify municipalities in any country/territory in the Americas with $\geq 5\%$ probability of having a projected Zika virus infection rate $\geq 10\%$ in 2017.

Results

In order to compare the modeling results, we provide a list of locations (state, province or department) for the eight priority countries, prioritized by the median rank of the models' outcomes. In **Tables 1–8** and **Figures 1–8** we provide the modeling results of the different models. We show the ranking of the different locations across models and compute a median rank. In addition, we provide the original results of the different models from which we construct the ranking of locations.

The results show that 18 locations (states, provinces, or departments) in six different countries ranked within the top quartile for the given country by two or more models. These locations are the following: Minas Gerais, São Paulo, and Maranhão states in Brazil; Nariño,

³MT3 includes Justin Lessler, Isabel Rodriguez-Barraquer, Derek Cummings, and Neil Ferguson.

Guajira, Córdoba, Bolívar, and Sucre states in Colombia; Monte Cristi, and Santiago provinces in Dominican Republic; Sucumbios and Los Ríos provinces in Ecuador; Sinaloa, San Luis Potosí, and Tamaulipas states in Mexico; Tumbes, Piura, Ucayali, and San Martín departments in Peru. For Costa Rica and Panama there are no locations ranked within the top quartile by two models. The median rank and range of model ranks (black line) for each state/province within each country are shown in **Figure 9**. The three models generate a relative ranking in each country; the ranking does not necessarily reflect an absolute risk or infer high virus transmission activity in the top-ranked locations. Locations may have low expected Zika transmission activity but still be ranked in the top places when compared to other places within the same country that show even lower activity.

Only five locations in two countries have a projected median Zika virus infection rate larger than 5% in 2017: Sucumbios, Esmeraldas, and Orellana provinces in Ecuador; and Tumbes and Piura departments in Peru (see **Tables 1-8**). When comparing across the three models, three of the previous five locations with a projected Zika virus infection rate larger than 5%, ranked within the top quartile for their country by two or more of the models: Sucumbios in Ecuador and Tumbes and Piura in Peru.

MT1 also offers the possibility of zooming in the different locations, allowing the study of the outbreak at the level of municipalities or urban areas. Through this analysis, we observe that 21 municipalities have a probability larger than 5% of having a projected Zika virus infection rate of at least 10% in 2017 (see **Table 9**). From the municipalities identified by MT1, nine of them are located within regions that are also identified by two or more of the models. The municipalities are the following:

- Colombia: Tumaco in Nariño state.
- Ecuador: Lago Agrio/Nueva Loja in Sucumbios province.
- Mexico: Los Mochis and Culiacan in Sinaloa state, and Tampico in Tamaulipas state.
- Peru: Piura in Piura department, Tumbes in Tumbes department, Tarapoto in San Martín department, and Pacallpa in Ucayali department.

In **Figures 1-8**, we provide a geographical visualization of the administrative units ranked in the tables. We use a color map associated to the rank order to localize places according to their likelihood of Zika transmission. The purpose of the maps is to illustrate any potential regional clustering of provinces/states with relatively higher likelihood of activity within each country. We again stress that the maps report the median ranking, as obtained by aggregating the results of the three models, and that the ranking is just indicative of the relative likelihood of future transmission within each country.

Summary

These preliminary findings provide states/provinces and municipalities in eight priority countries where study sites may have increased likelihood of having sufficient Zika virus transmission to meet the efficacy end points in 2017. Due to substantial differences and uncertainties in data between countries, we limited the comparisons to estimates for subnational areas within each of the priority countries.

All of the evaluated subnational areas in the priority countries had low projected incidence rates in 2017. Only three provinces or departments in two countries had a projected Zika virus infection rate >5% and ranked within the top quartile for their country by two or more

of the models. We also identified relatively few municipalities that have a projected Zika virus infection rate $\geq 10\%$ and are located in states with consistently high rankings by two or more of the models.

In summary, the models suggest that the total number of participants, number of study sites, and/or duration of study follow-up may need to be increased to meet the efficacy end points. The findings also support initiating a high number of study sites in multiple geographic areas to maximize the likelihood of having study capacity in one or more areas that experience Zika virus infections in 2017 and provide flexibility to responsively increase enrollment in areas with the highest incidence of infection.

This report is made available to share the approach and preliminary findings with the research community. Results should be interpreted cautiously given the model limitations and assumptions. Furthermore, projecting the Zika virus transmission at seasonal and longer timescales increases uncertainty, especially given the lack of comprehensive, quality surveillance data on current and previous Zika virus transmission activity. The modeling teams are continuing these efforts and will provide an updated report which will incorporate: 1) refined modeling methods, 2) updated surveillance data, and 3) further integration and discussion of similarities and differences between the model findings.

Funding sources

CMB, TAP, RCR, IRB, and ASS acknowledge support from a RAPID grant from the National Science Foundation (DEB 1641130), and TAP and ASS acknowledge support from a DARPA Young Faculty Award (D16AP00114). MEH, IML and AV are supported by Models of Infectious Disease Agent Study, National Institute of General Medical Sciences Grant U54GM111274. IML is partially supported by the WHO Research and Development Blueprint for Action to Prevent Epidemics. NF acknowledges support from the UK Medical Research Council, the NIGMS MIDAS Initiative and the Bill and Melinda Gates Foundation for research funding. JL and IRB acknowledge support from NIH Grant R01 AI102939-01A1. JL, AP and AV acknowledge support from NIH supplement Grant R01 AI102939-05. AJM acknowledges support to NCAR from a CDC Intergovernmental Personnel Agreement (17IPA1708912); NCAR is also supported by the National Science Foundation.

Competing Interests: AV has received research funding unrelated to this paper (through his employer Northeastern University) from Metabiota Inc.

References

1. Balcan D, Gonçalves B, Hu H, et al. Modeling the spatial spread of infectious diseases: The global epidemic and mobility computational model. *J Computational Sci* 2010;1:132–45.
2. Balcan D, Colizza V, Gonçalves B, Hu H, Ramasco JJ, Vespignani A, Multiscale mobility networks and the spatial spreading of infectious diseases. *PNAS* 2009;106:21484–9.
3. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French Polynesia, South Pacific. *Emerg Infect Dis* 2013;20:1085–86.
4. Chevalier MS, Biggerstaff BJ, Basavaraju SV, et al. Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016. *Emerg Infect Dis* 2017;23:790–5.
5. Cummings DAT, Iamsirithaworn S, Lessler JT, McDermott A, Prasanthong R, Nisalak A, Jarman RG, Burke DS, Gibbons RV. The impact of the demographic transition on dengue in

- Thailand: Insights from a statistical analysis and mathematical modeling. *PLoS Med* 2009; 6:e1000139.
6. Dick GWA, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg* 1952;46:509–20.
7. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med* 2009;360:2536–2543.
8. Ferguson NM, Cucunubá ZM, Dorigatti I, et al. Countering the Zika epidemic in Latin America. *Science* 2016. 10.1126/science.aag0219
9. Gomes M, Pastore-Piontti A, Rossi L, et al. Assessing the international spreading risk associated with the 2014 West African Ebola outbreak. *PLoS* 2014. doi:10.1371/currents.outbreaks.cd818f63d40e24aef769dda7df9e0da5.
10. Heang V, Yasuda CY, Sovann L, et al. Zika virus infection, Cambodia, 2010. *Emerg Infect Dis* 2012;18:349.
11. Ikejezie J, Shapiro CN, Kim J, et al. Zika virus transmission — Region of the Americas, May 15, 2015–December 15, 2016. *MMWR Morb Mortal Wkly Rep* 2017;66:329–34.
12. Kucharski, A.J., Funk, S., Eggo, R.M. et al. Transmission dynamics of Zika virus in island populations: Modeling analysis of the 2013–14 French Polynesia outbreak. *PLoS Negl Trop Dis* 2016;10:e0004726.
13. Moore CA, Staples JE, Dobyns WB. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. *JAMA Pediatr* 2017;171:288–95.
14. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. *Clin Microbiol Infect* 2014;20:O595–O596.
15. Perkins TA, Siraj AS, Ruktanonchai CW, Kraemer MUG, Tatem AJ. Model-based projections of Zika virus infections in childbearing women in the Americas. *Nature Microbiol* 2016;16126.
16. Petersen LR, Jamieson DJ, Powers AM, Honein MA. *N Engl J Med* 2016;374:1552–63.
17. Poletto C, Gomes M, Pastore-Piontti A, et al. Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. *Eurosurveill* 2014;19:20936.
18. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects--Reviewing the evidence for causality. *N Engl J Med* 2016;374:1981–7.
19. Rodríguez-Barraquer I, Salje H, Lessler J, Cummings DAT. Predicting intensities of Zika infection and microcephaly using transmission intensities of other arboviruses. *BioRxiv* 2016 <http://dx.doi.org/10.1101/041095>
20. Roth A, Mercier A, Lepers C, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections — An unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014. *Euro Surveill* 2014;19.
21. Thomas SJ. Zika virus vaccines — A full field and looking for closers. *N Eng J Med* 2017;376:1883–6.
22. Tizzoni M, Bajardi P, Poletto C, et al. Real-time numerical forecast of global epidemic spreading: Case study of 2009 A/H1N1pdm. *BMC Medicine* 2012;10:165.
23. Zanoluca C, Melo VCAd, Mosimann ALP, Santos GIVd, Santos CNDd, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Memórias do Instituto Oswaldo Cruz* 2015;110:569–572.
24. Zhang Q, Sun K, Chinazzi M, Pastore y Piontti A, et al. Spread of Zika virus in the Americas. *PNAS* 2017;114:E4334–E4343.

Table 1: Brazil modeling results by state.

State	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Infection rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Minas Gerais	1	1	19	1	19,987,031	0.06%	(0.00-0.35)	13.2%	(6.8-21.5)	0.023
São Paulo	3	2	26	3	41,315,532	0.01%	(0.00-0.03)	6.0%	(4.1-13.3)	0.106
Maranhão	5	12	5	5	6,401,099	<0.01%		32.1%	(29.1-35.3)	0.224
Amazonas	8	12	3	--	3,585,205	<0.01%		33.9%	(27.2-40.2)	--
Ceará	8	12	4	8	8,382,131	<0.01%		33.5%	(30.2-36.4)	0.316
Mato Grosso	9	3	27	9	3,060,605	<0.01%	(0.00-0.07)	3.2%	(-29.6-20.1)	0.443
Mato Grosso do Sul	9	9	7	16	2,506,342	<0.01%	(0.00-0.52)	30.2%	(27.0-34.5)	0.676
Pará	10	12	10	2	7,438,518	<0.01%		27.3%	(25.1-30.3)	0.03
Rio Grande do Sul	10	10	22	6	10,482,802	<0.01%	(0.00-0.03)	11.5%	(4.5-19.9)	0.268
Rondônia	11	11	17	4	1,576,505	<0.01%	(0.00-0.02)	22.5%	(18.5-26.3)	0.124
Rio de Janeiro	11	5	21	11	14,324,781	<0.01%	(0.00-0.03)	11.8%	(-4.2-20.6)	0.502
Rio Grande do Norte	12	12	6	20	3,023,570	<0.01%		31.5%	(26.5-35.2)	0.799
Roraima	12	12	1	23	456,864	<0.01%		37.9%	(31.3-44.1)	0.962
Piauí	12	12	2	15	3,377,661	<0.01%		36.2%	(33.9-39.3)	0.666
Tocantins	12	12	14	7	1,435,936	<0.01%		24.6%	(14.7-30.5)	0.275
Distrito Federal	12	12	23	10	2,647,348	<0.01%		7.4%	(0.9-18.1)	0.448
Acre	12	12	13	12	708,021	<0.01%		26.2%	(20.1-30.2)	0.522
Pernambuco	12	12	9	19	7,766,940	<0.01%		29.1%	(26.2-32.5)	0.79
Alagoas	12	8	12	18	2,812,590	<0.01%	(0.00-0.01)	26.7%	(19.3-31.6)	0.761
Sergipe	12	12	8	21	1,991,960	<0.01%		29.9%	(27.3-32.3)	0.883
Paraíba	12	12	11	22	3,619,622	<0.01%		27.1%	(22.5-31.4)	0.948
Goiás	13	12	16	13	6,205,103	<0.01%		23.9%	(18.8-28.8)	0.53
Bahia	14	12	20	14	12,687,903	<0.01%		12.1%	(-6.2-22.3)	0.66
Espírito Santo	15	4	15	17	2,682,726	<0.01%	(0.00-0.01)	24.4%	(19.9-28.3)	0.735
Amapá	15	12	18	--	594,387	<0.01%		20.7%	(17.7-22.8)	--
Santa Catarina	16	7	24	--	5,417,796	<0.01%	(0.00-0.34)	7.3%	(2.8-16.1)	--
Paraná	16	6	25	--	10,616,043	<0.01%	(0.00-0.63)	6.8%	(4.3-14.8)	--

*Median and 95% confidence intervals for projected infection rates in 2017 from >1,000 simulations.

† Proportion of the population still at risk for infection.

Table 2: Colombia modeling results by state.

State	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Nariño	2	2	19	2	1,766,008	0.50%	(0.04-2.17)	2.7%	(1.6-5.7)	0.074
La Guajira	3	1	3	4	985,498	0.58%	(0.01-3.46)	30.2%	(24.1-35.9)	0.137
Córdoba	4	4	1	11	1,736,218	0.26%	(0.02-1.00)	33.5%	(30.0-37.1)	0.301
Bolívar	5	9	4	5	2,122,021	0.05%	(0.00-0.23)	29.8%	(23.8-34.4)	0.157
Sucre	7	5	7	7	859,909	0.16%	(0.01-0.77)	27.3%	(17.3-33.5)	0.205
Antioquia	9	8	18	9	6,534,764	0.06%	(0.01-0.39)	3.7%	(1.0-10.6)	0.227
Guainía	9	13	5	--	42,123	0.01%	(0.00-16.07)	28.8%	(25.3-32.0)	--
Cauca	10	10	15	3	1,391,889	0.05%	(0.00-0.30)	7.8%	(5.6-10.2)	0.135
Magdalena	11	6	11	16	1,272,278	0.16%	(0.02-0.70)	18.9%	(5.0-26.6)	0.561
Cesar	11	11	9	12	1,041,203	0.02%	(0.00-0.18)	26.7%	(17.6-32.8)	0.330
Vichada	12	12	2	17	73,702	0.02%	(0.00-10.75)	31.9%	(24.3-37.9)	0.620
Choco	12	23	12	8	505,046	<0.01%		13.5%	(5.4-21.9)	0.222
Caquetá	13	7	13	19	483,834	0.06%	(0.01-0.36)	9.5%	(-4.0-17.5)	0.641
Risaralda	14	14	22	13	957,250	<0.01%	(0.00-0.03)	0.1%	(-8.4-9.6)	0.370
Vaupés	14	17	10	--	44,079	<0.01%	(0.00-1.43)	23.8%	(17.4-27.6)	--
Atlántico	14	20	8	14	2,489,709	<0.01%	(0.00-0.01)	27.1%	(12.1-37.0)	0.404
Caldas	15	15	20	1	989,942	<0.01%	(0.00-0.02)	1.6%	(-0.8-5.7)	0.068
Putumayo	16	3	16	18	349,537	0.38%	(0.03-3.02)	7.3%	(-5.1-16.5)	0.632
Guaviare	16	16	6	21	112,621	<0.01%	(0.00-0.19)	28.6%	(17.2-36.4)	0.774
Boyacá	19	19	21	6	1,278,061	<0.01%	(0.00-0.01)	1.2%	(-0.3-2.1)	0.169
Amazonas	19	23	14	--	77,088	<0.01%		9.0%	(-18.3-22.2)	--
Meta	20	21	17	20	979,683	<0.01%	(0.00-0.01)	5.4%	(-19.1-17.2)	0.768
Cundinamarca	23	23	24	15	2,721,368	<0.01%		-0.6%	(-3.3-0.6)	0.496
Quindío	23	23	23	10	568,473	<0.01%		-0.1%	(-4.6-11.2)	0.235
Santander	23	23	27	23	2,071,044	<0.01%		-6.6%	(-32.9-6.3)	0.829
Tolima	23	23	25	22	1,412,230	<0.01%		-1.5%	(-29.1-11.5)	0.793
Huila	24	18	29	24	1,168,910	<0.01%	(0.00-0.01)	-9.5%	(-41.2-5.2)	0.832
Norte Santander	25	22	31	25	1,367,716	<0.01%	(0.00-0.01)	-19.8%	(-71.1-4.3)	0.837
Valle	26	23	26	26	4,660,438	<0.01%		-5.2%	(-38.8-11.1)	0.871
Arauca	27	23	28	27	265,190	<0.01%		-7.1%	(-44.2-11.3)	0.962
Casanare	28	23	30	28	362,698	<0.01%		-16.7%	(-73.6-11.9)	0.993

*Median and 95% confidence intervals for projected infection rates in 2017 from >1,000 simulations.

† Proportion of the population still at risk for infection.

Table 3: Costa Rica modeling results by province.

Province	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Limon	3	2	4	--	386,862	<0.01%	(0.00-3.99)	3.0%	(-0.7-13.8)	
Puntarenas	3	3	2	--	410,929	<0.01%	(0.00-1.03)	7.8%	(-0.6-15.7)	
Guanacaste	3	5	1	--	354,154	<0.01%		16.5%	(10.6-22.1)	
Cartago	4	1	7	--	490,903	<0.01%	(0.00-1.51)	0.8%	(0.2-3.5)	
Alajuela	4	5	3	--	885,571	<0.01%		6.1%	(3.1-15.3)	
San Jose	5	4	6	--	1,404,242	<0.01%	(0.00-0.38)	1.3%	(0.1-7.8)	
Heredia	5	5	5	--	433,677	<0.01%		1.8%	(0.5-10.1)	

*Median and 95% confidence intervals for projected infection rates in 2017 from >1,000 simulations.

† Proportion of the population still at risk for infection.

Table 4: Dominican Republic modeling results by province.

Province	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Monte Cristi	2	1	3	--	116,848	<0.01%	(0.00-0.01)	33.9%	(30.6-37.4)	
Santiago	4	6	2	--	970,653	<0.01%	(0.00-0.01)	34.1%	(30.2-37.9)	
Valverde	6	10	1	--	162,117	<0.01%	(0.00-0.01)	34.9%	(30.9-39.2)	
Españat	7	3	10	--	301,254	<0.01%	(0.00-0.01)	31.6%	(29.0-33.8)	
Sánchez Ramírez	7	8	6	--	182,808	<0.01%	(0.00-0.01)	33.0%	(29.9-36.0)	
Hermanas Mirabal	8	2	14	--	96,647	<0.01%	(0.00-0.01)	30.2%	(27.3-33.0)	
La Romana	9	14	4	--	196,134	<0.01%		33.3%	(29.7-36.8)	
Duarte	10	11	9	--	318,669	<0.01%	(0.00-0.01)	31.7%	(28.9-35.4)	
Dajabón	10	12	8	--	137,343	<0.01%	(0.00-0.01)	32.9%	(30.1-36.0)	
Monseñor Nouel	10	14	6	--	159,403	<0.01%		33.0%	(29.4-37.0)	
San Pedro de Macorís	10	14	5	--	230,075	<0.01%		33.2%	(29.2-36.9)	
Puerto Plata	11	5	16	--	304,307	<0.01%	(0.00-0.01)	29.1%	(27.4-31.3)	
Baoruco	12	14	10	--	98,386	<0.01%		31.6%	(29.6-34.4)	
Santiago Rodríguez	13	13	13	--	57,191	<0.01%	(0.00-0.01)	30.3%	(28.8-32.7)	
María Trinidad Sánchez	13	14	12	--	129,287	<0.01%		30.9%	(28.7-33.1)	
San Juan	14	4	23	--	244,052	<0.01%	(0.00-0.01)	25.4%	(22.3-28.5)	
La Vega	14	7	20	--	372,969	<0.01%	(0.00-0.01)	25.9%	(23.6-28.8)	
La Estrelleta/Elias Pina	15	9	21	--	86,066	<0.01%	(0.00-0.01)	25.8%	(23.1-28.7)	
San Cristóbal	15	14	15	--	446,468	<0.01%		29.9%	(27.9-32.0)	
Monte Plata	16	14	17	--	206,972	<0.01%		27.7%	(24.8-30.2)	
Peravia	16	14	18	--	175,038	<0.01%		26.6%	(24.5-28.8)	
La Altagracia	17	14	19	--	263,460	<0.01%		26.2%	(21.8-28.9)	
El Seibo	18	14	22	--	92,467	<0.01%		25.7%	(21.0-28.2)	
Barahona	19	14	24	--	143,242	<0.01%		25.3%	(23.4-27.7)	
Azua	20	14	25	--	221,137	<0.01%		24.8%	(22.5-26.4)	
Independencia	20	14	26	--	62,587	<0.01%		24.6%	(22.5-26.9)	
Hato Mayor	21	14	28	--	75,665	<0.01%		23.2%	(18.3-27.4)	
Santo Domingo	21	14	27	--	2,559,326	<0.01%		23.6%	(21.0-25.8)	
Distrito Nacional	22	14	30	--	845,598	<0.01%		18.2%	(15.4-21.2)	
Samaná	22	14	29	--	88,288	<0.01%		20.3%	(16.8-23.2)	
San José de Ocoa	22	14	32	--	58,322	<0.01%		0.9%	(-0.7-11.0)	
Pedernales	23	14	31	--	44,944	<0.01%		17.2%	(15.1-20.3)	

*Median and 95% confidence intervals for projected infection rates in 2017 from >1,000 simulations.

† Proportion of the population still at risk for infection.

Table 5: Ecuador modeling results by province.

Province	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Sucumbíos	4	1	6	--	186,504	7.55%	(0.21-15.90)	14.8%	(6.6-24.4)	
Los Ríos	5	5	4	--	777,079	0.81%	(0.07-3.59)	18.6%	(12.9-24.9)	
Esmeraldas	5	2	8	--	555,848	5.81%	(0.43-12.96)	12.0%	(5.3-21.2)	
Orellana	6	3	9	--	88,611	5.43%	(0.38-12.54)	8.6%	(4.1-19.9)	
Manabí	7	6	7	--	1,281,663	0.55%	(0.05-1.83)	13.0%	(2.5-21.3)	
Guayas	7	11	2	--	3,595,034	0.02%	(0.00-0.13)	27.7%	(24.4-30.4)	
El Oro	8	13	3	--	613,666	<0.01%	(0.00-0.62)	23.0%	(18.9-27.3)	
Santa Elena	8	15	1	--	292,220	<0.01%	(0.00-0.01)	30.0%	(27.0-32.8)	
Pastaza	9	4	14	--	87,380	3.07%	(0.49-6.55)	2.8%	(1.1-12.3)	
Bolívar	12	7	16	--	200,410	0.51%	(0.04-2.36)	1.4%	(0.3-6.3)	
Napo	12	8	16	--	106,649	0.48%	(0.06-1.30)	1.4%	(0.2-10.8)	
Morona Santiago	12	12	12	--	153,622	0.02%	(0.00-0.31)	5.6%	(2.2-16.2)	
Galápagos	12	19	5	--	20,541	<0.01%		16.6%	(10.6-21.6)	
Cotopaxi	14	10	18	--	394,132	0.24%	(0.02-1.21)	0.7%	(0.1-2.7)	
Cañar	14	17	10	--	234,668	<0.01%	(0.00-0.02)	6.9%	(5.0-8.7)	
Carchi	15	9	20	--	155,648	0.34%	(0.00-1.64)	0.0%	(0.0-0.3)	
Zamora Chinchipe	15	14	15	--	105,214	<0.01%	(0.00-0.24)	2.2%	(0.2-13.3)	
Loja	15	16	13	--	450,634	<0.01%	(0.00-0.17)	3.6%	(2.3-7.6)	
Santo Domingo Tsáchilas	15	19	11	--	422,080	<0.01%		6.0%	(1.6-17.8)	
Azuay	18	18	18	--	726,744	<0.01%	(0.00-0.03)	0.7%	(0.5-1.1)	
Chimborazo	20	19	20	--	468,077	<0.01%		0.0%	(0.0-0.2)	
Imbabura	20	19	20	--	394,164	<0.01%		0.0%	(0.0-0.3)	
Pichincha	20	19	20	--	2,449,094	<0.01%		0.0%	(-0.1-0.3)	
Tungurahua	20	19	20	--	530,294	<0.01%		0.0%	(0.0-0.0)	

*Median and 95% confidence intervals for projected infection rates in 2017 from >1,000 simulations.

† Proportion of the population still at risk for infection.

Table 6: Mexico modeling results by state

State	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Suss. pop	(95%CI)	MT3 Score
Sinaloa	1	1	1	4	2,838,630	2.44%	(0.02-14.95)	38.5%	(31.2-44.1)	0.166
San Luis Potosí	4	4	19	1	2,626,925	0.33%	(0.00-4.29)	10.0%	(9.0-10.9)	0.002
Tamaulipas	5	5	2	7	2,684,165	0.28%	(0.00-3.86)	37.4%	(29.7-42.6)	0.286
Sonora	9	3	9	14	2,663,174	0.58%	(0.03-1.65)	29.1%	(25.5-32.8)	0.552
Quintana Roo	10	10	7	19	1,127,393	0.03%	(0.00-1.56)	30.6%	(25.5-34.1)	0.695
Baja California Sur	11	2	11	17	569,628	1.55%	(0.12-4.85)	25.4%	(22.4-28.4)	0.622
Nayarit	11	8	12	11	10,443,171	0.05%	(0.00-11.01)	24.7%	(20.6-27.7)	0.405
Campeche	12	12	6	22	799,030	0.02%	(0.00-1.29)	30.9%	(24.9-35.2)	0.797
Nuevo León	12	21	3	12	4,881,286	<0.01%	(0.00-0.29)	35.1%	(27.5-40.1)	0.468
Veracruz	14	6	14	26	7,620,285	0.18%	(0.00-4.59)	21.5%	(19.8-22.9)	0.936
Guerrero	14	14	10	21	3,479,330	0.01%	(0.00-2.08)	26.8%	(24.8-28.8)	0.754
Chihuahua	15	13	17	--	3,309,967	0.01%	(0.00-0.06)	15.4%	(8.9-18.9)	--
Colima	15	15	7	25	671,505	0.01%	(0.00-18.45)	30.6%	(26.4-34.1)	0.846
Coahuila	15	25	15	15	3,197,854	<0.01%	(0.00-0.01)	20.0%	(15.4-22.9)	0.614
Chiapas	16	9	16	16	4,960,867	0.04%	(0.00-2.50)	15.8%	(14.0-20.1)	0.615
Jalisco	16	16	21	8	7,708,204	0.01%	(0.00-1.61)	6.4%	(3.2-18.2)	0.331
Michoacán	17	17	20	2	4,448,339	0.01%	(0.00-6.27)	6.8%	(6.2-9.2)	0.023
Oaxaca	18	7	18	20	3,846,384	0.11%	(0.00-5.65)	13.0%	(11.5-17.5)	0.697
Hidalgo	18	11	24	18	3,058,115	0.02%	(0.00-0.42)	3.6%	(2.7-4.5)	0.651
Durango	18	18	22	6	1,315,740	<0.01%	(0.00-1.24)	4.8%	(3.4-15.0)	0.280
Tabasco	19	19	5	23	2,301,101	<0.01%	(0.00-0.80)	32.3%	(28.9-35.7)	0.808
Puebla	20	20	25	9	6,319,334	<0.01%	(0.00-0.73)	2.8%	(2.3-4.3)	0.354
Yucatán	22	22	4	27	2,018,565	<0.01%	(0.00-0.04)	33.3%	(28.1-37.4)	0.957
Zacatecas	23	23	28	13	1,582,975	<0.01%	(0.00-0.06)	0.6%	(0.3-3.6)	0.507
Guanajuato	23	24	23	10	5,825,418	<0.01%	(0.00-0.07)	4.1%	(0.5-15.1)	0.382
Morelos	24	26	13	24	1,876,080	<0.01%		23.2%	(19.2-27.4)	0.837
Baja California	26	26	26	--	3,059,921	<0.01%		1.5%	(0.8-10.2)	--
México	26	26	30	3	17,214,830	<0.01%		0.2%	(0.2-0.4)	0.143
Querétaro	26	26	27	5	1,932,829	<0.01%		0.9%	(0.7-4.2)	0.272
Aguascalientes	28	26	29	--	1,206,312	<0.01%		0.5%	(0.0-12.9)	
Distrito Federal	29	26	31	--	7,924,645	<0.01%		0.0%	(0.0-0.0)	
Tlaxcala	29	26	31	--	1,066,673	<0.01%		0.0%	(0.0-0.0)	

*Median and 95% confidence intervals for projected infection rates in 2017 from > 1,000 simulations.

† Proportion of the population still at risk for infection.

Table 7: Panama results by province

Province	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Herrera	4	7	1	--	99,504	<0.01%	(0.00-0.13)	30.3%	(27.5-33.6)	
Los Santos	5	8	2	--	107,876	<0.01%	(0.00-0.01)	29.3%	(26.9-31.7)	
Emberá	6	4	8	--	34,319	0.01%	(0.00-0.45)	19.3%	(12.0-25.3)	
Veraguas	6	5	6	--	225,085	<0.01%	(0.00-0.14)	23.2%	(18.2-25.8)	
Ngäbe Buglé	7	1	12	--	152,129	0.02%	(0.00-0.47)	5.1%	(2.5-15.1)	
Bocas del Toro	7	2	11	--	106,106	0.02%	(0.00-0.59)	11.3%	(6.8-16.4)	
Darién	7	3	10	--	46,615	0.01%	(0.00-0.68)	14.0%	(8.1-22.0)	
Panamá	7	11	3	--	1,207,922	<0.01%		25.5%	(23.4-27.5)	
Colón	8	9	7	--	221,879	<0.01%	(0.00-0.00)	21.6%	(18.2-24.7)	
Chiriquí	8	6	9	--	437,495	<0.01%	(0.00-0.12)	17.2%	(13.9-20.1)	
Coclé	8	11	4	--	218,284	<0.01%		24.8%	(22.2-26.4)	
Panamá Oeste	8	11	5	--	358,910	<0.01%		24.5%	(21.8-26.4)	
Guna Yala	12	10	13	--	3,808	<0.01%	(0.00-0.13)	-183.3%	(-427.6--61.6)	

*Median and 95% confidence intervals for projected infection rates in 2017 from > 1,000 simulations.

† Proportion of the population still at risk for infection.

Table 8: Peru modeling results by department.

Department	Median Rank	MT1 Rank	MT2 Rank	MT3 Rank	Population	MT1* Inf. rate	(95% CI)	MT2† Susc. pop	(95%CI)	MT3 Score
Tumbes	2	2	2	--	193,544	6.31%	(0.00-35.76)	29.7%	(26.9-32.6)	
Piura	3	1	4	--	1,707,749	7.10%	(0.00-22.54)	18.9%	(15.5-24.5)	
Loreto	4	7	1	--	976,542	0.03%	(0.00-8.14)	30.7%	(25.2-33.8)	
Ucayali	5	6	3	--	464,972	0.06%	(0.00-23.78)	28.4%	(25.4-31.7)	
San Martín	5	4	6	--	774,056	0.10%	(0.00-24.73)	16.8%	(11.8-24.2)	
Lambayeque	6	5	7	--	1,140,486	0.06%	(0.00-0.32)	10.7%	(5.1-22.2)	
Cajamarca	8	3	12	--	1,455,633	0.17%	(0.00-0.81)	2.6%	(1.7-5.1)	
Madre de Dios	8	10	5	--	121,804	<0.01%		18.1%	(12.9-24.2)	
Amazonas	9	10	8	--	427,666	<0.01%		8.2%	(5.9-13.6)	
Callao	10	10	9	--	260,540	<0.01%		4.0%	(0.0-18.6)	
Junín	10	10	10	--	1,249,333	<0.01%		2.8%	(1.6-5.2)	
Lima Province	10	10	10	--	7,957,501	<0.01%		2.8%	(0.0-14.6)	
Huánuco	11	8	13	--	817,699	<0.01%	(0.00-1.11)	2.5%	(1.4-5.6)	
Pasco	12	9	14	--	286,905	<0.01%	(0.00-0.14)	1.9%	(1.1-4.2)	
Cuzco	13	10	15	--	1,255,116	<0.01%		1.0%	(0.6-2.0)	
La Libertad	13	10	16	--	1,723,072	<0.01%		0.8%	(0.1-7.6)	
Ayacucho	14	10	18	--	651,575	<0.01%		0.3%	(0.2-0.9)	
Lima	14	10	17	--	1,462,706	<0.01%		0.4%	(0.0-4.6)	
Ancash	15	10	20	--	1,097,634	<0.01%		0.1%	(0.0-4.0)	
Puno	15	10	19	--	1,488,142	<0.01%		0.2%	(0.1-0.5)	
Apurímac	16	10	21	--	434,423	<0.01%		0.0%	(0.0-0.0)	
Arequipa	16	10	21	--	1,187,531	<0.01%		0.0%	(0.0-0.0)	
Huancavelica	16	10	21	--	491,764	<0.01%		0.0%	(0.0-0.0)	
Ica	16	10	21	--	719,368	<0.01%		0.0%	(0.0-3.3)	
Moquegua	16	10	21	--	173,112	<0.01%		0.0%	(0.0-0.1)	
Tacna	16	10	21	--	308,111	<0.01%		0.0%	(0.0-0.1)	

*Median and 95% confidence intervals for projected infection rates in 2017 from > 1,000 simulations.

† Proportion of the population still at risk for infection.

Table 9: Probability of projected annual Zika virus infection rates $\geq 10\%$ in 2017 for municipalities in the Americas

Country	State	Municipality	Municipality population	Model 1 Probability of infection rate $\geq 10\%$ in 2017	(95% CI)
Ecuador	Sucumbios	Lago Agrio/Nueva Loja	249,959	49%	(46-52)
Peru	Tumbes	Tumbes	283,424	48%	(45-51)
Peru	Piura	Piura	1,730,114	45%	(43-48)
Mexico	Sinaloa	Los Mochis	1,049,654	40%	(38-43)
Bolivia	Gran Chaco	Yacuiba	243,077	27%	(24-29)
Ecuador	Orellana	El Coca	151,629	21%	(19-24)
Paraguay	Alto Parana	Ciudad del Este	2,336,625	21%	(19-23)
Mexico	Tamaulipas	Tampico	1,835,390	18%	(16-20)
Honduras	Gracias a Dios	Puerto Lempira	106,834	16%	(14-18)
Ecuador	Esmeraldas	Esmeraldas	599,629	12%	(10-14)
Peru	San Martin	Tarapoto	1,397,529	10%	(9-12)
Colombia	Narino	Tumaco	275,111	9%	(7-10)
Peru	Ucayali	Pucallpa	694,810	8%	(7-10)
Mexico	Colima	Colima	957,465	8%	(6-9)
Mexico	Baja California Sur	Cabo San Jose	149,391	8%	(6-9)
Honduras	Colon	Guanaja/Tocoa	221,233	6%	(5-8)
Colombia	Guainia	Puerto Inirida	53,718	6%	(5-8)
Mexico	Michoacan	Lazaro Cardenas	341,119	6%	(4-7)
Mexico	Sinaloa	Culiacan	1,481,563	5%	(4-7)
Colombia	Vichada	Puerto Carreno	39,127	5%	(4-6)
Venezuela	Bolivar	Santa Elena	8,160	5%	(3-6)
Mexico	Oaxaca	Santa Maria Huatulco	665,936	4%	(3-6)
Mexico	Oaxaca	Puerto Escondido	464,002	4%	(3-5)
Mexico	Colima	Manzanillo	390,234	4%	(3-5)
Mexico	Chiapas	Tapachula	921,029	3%	(2-4)
Mexico	Nayarit	Tepic	934,532	3%	(2-4)
Mexico	Sinaloa	Mazatlan	699,002	3%	(2-4)
Brazil	Parana	Umuarama	518,546	3%	(2-4)
Mexico	Veracruz	Minatitlan	1,881,784	3%	(2-4)
Colombia	Amazonas	Tarapaca	50,271	2%	(2-3)

Figure 1: Median rank for the three models for each state in Brazil. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 2: Median rank for the three models for each state in Colombia. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 3: Median rank for the three models for each province in Costa Rica. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 4: Median rank for the three models for each province in Dominican Republic. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 5: Median rank for the three models for each province in Ecuador. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 6: Median rank for the three models for each state in Mexico. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 7: Median rank for the three models for each province in Panama. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 8: Median rank for the three models for each department in Peru. The color scheme shows how each state ranks within the country. That is, the lower the rank (dark blue), the higher the relative likelihood of future Zika transmission.

Figure 9: Median rank (red dot) and range of model ranks (black line) for each state/province within each country. Individual models are indicated by open blue shapes (square = Model 1; cross = Model 2; diamond = Model 3). Additional details can be found in Tables 1-8.